IL4 and Alzheimer disease: Dupilumab, an anti-interleukin-4/13 receptor monoclonal antibody that inhibits the differentiation of naïve T-cells into the Th2 subtype, is presently endorsed for the management of moderate to severe atopic dermatitis (AD) [10].